Patents by Inventor Stuart L. Emanuel

Stuart L. Emanuel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NUCLEIC ACID CONSTRUCTS ENCODING KALLIKREIN-2 FUSION PROTEIN AND VECTORS, PREPARATIONS OF CELLS, AND METHODS OF USE THEREOF
    Publication number: 20220403397
    Abstract: The present invention relates to a recombinant nucleic acid construct encoding a kallikrein-2 fusion protein. The kallikrein-2 fusion protein includes a first nucleotide sequence encoding kallikrein-2 (KLK2), and a second nucleotide sequence encoding a glycosylphophatidylinositol (GPI) attachment sequence, where the GPI attachment sequence encoding nucleotide sequence is positioned 3? to the KLK2 encoding nucleotide sequence.
    Type: Application
    Filed: June 8, 2022
    Publication date: December 22, 2022
    Inventors: Stuart L. EMANUEL, Thomas J. RUTKOSKI
  • Substituted pyrimidinyl oxime kinase inhibitors
    Patent number: 8367825
    Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: February 5, 2013
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Xu Guozhang, Lily Lee, Terry V. Hughes, Steven K. Wetter, Peter J. Connolly, Marta C. Abad, Stuart L. Emanuel, Prabha S. Kamachi, Steven A. Middleton, Kathleen A. Battista, Gilles C. Bignan
  • 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives
    Patent number: 8299082
    Abstract: 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: October 30, 2012
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Shenlin Huang, Ronghui Lin, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton, Robert H. Gruninger, Steven K. Wetter
  • Substituted Pyrimidinyl Oxime Kinase Inhibitors
    Publication number: 20120157412
    Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Application
    Filed: February 28, 2012
    Publication date: June 21, 2012
    Inventors: Kathleen A. Battista, Gilles C. Bignan, Guozhang Xu, Lily Lee, Terry V. Hughes, Steven K. Wetter, Peter J. Connolly, Marta C. Abad, Stuart L. Emanuel, Prabha S. Karnachi, Steven A. Middleton
  • Substituted pyrimidinyl oxime kinase inhibitors
    Patent number: 8153791
    Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Grant
    Filed: December 12, 2006
    Date of Patent: April 10, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Guozhang Xu, Lily Lee, Terry V. Hughes, Steven K. Wetter, Peter J. Connolly, Marta C. Abad, Stuart L. Emanuel, Prabha S. Karnachi, Steven A. Middleton, Kathleen A. Battista, Gilles C. Bignan
  • 1,2,4-TRIAZOLYLAMINOARYL (HETEROARYL) SULFONAMIDE DERIVATIVES
    Publication number: 20110077249
    Abstract: 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.
    Type: Application
    Filed: September 29, 2010
    Publication date: March 31, 2011
    Applicant: Janssen Pharmaceutica N.V.
    Inventors: Shenlin Huang, Ronghui Lin, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton, Robert H. Gruninger, Steven K. Wetter
  • 1,2,4-Triazolylaminoaryl (heteroaryl) sulfonamide derivatives
    Patent number: 7888380
    Abstract: 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.
    Type: Grant
    Filed: October 6, 2005
    Date of Patent: February 15, 2011
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Shenlin Huang, Ronghui Lin, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton, Robert H. Gruninger, Steven K. Wetter
  • Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
    Patent number: 7855205
    Abstract: The present invention provides pyrimidinyl substituted fused-pyrrolyl compounds of Formula (I) and pharmaceutical compositions comprising the compounds and methods of synthesis and use thereof. The compounds are kinase inhibitors useful in treating or ameliorating a kinase mediated, angiogenesis-mediated or hyperproliferative disorder. The invention thus also provides a therapeutic or prophylactic method of use for the compounds and/or pharmaceutical compositions to treat such disorders.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: December 21, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Shenlin Huang, Ronghua Li, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton
  • SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS
    Publication number: 20080300264
    Abstract: The present invention is directed to substituted thiatriazaacenaphthylene-6-carbonitrile compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Application
    Filed: August 14, 2008
    Publication date: December 4, 2008
    Inventors: Peter J. Connolly, Stuart L. Emanuel, Stuart Hayden, Sigmond G. Johnson, Bharat Lagu, Steven A. Middleton, Niranjan B. Pandey, Mark T. Powell
  • SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS
    Publication number: 20080293785
    Abstract: The present invention is directed to substituted benzothiazole compounds of formula (I): and forms thereof, their synthesis and use for treating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Application
    Filed: April 10, 2007
    Publication date: November 27, 2008
    Inventors: Peter J. Connolly, Stuart L. Emanuel, Shenlin Huang, Ignatius J. Turchi
  • Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
    Patent number: 7427625
    Abstract: The present invention is directed to substituted thiatriazaacenaphthylene-6-carbonitrile compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: September 23, 2008
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Peter J. Connolly, Stuart L. Emanuel, Stuart Hayden, Sigmond G. Johnson, Bharat Lagu, Steven A. Middleton, Niranjan B. Pandey, Mark T. Powell
  • SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS
    Publication number: 20080108611
    Abstract: The present invention is directed to thienopyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Application
    Filed: January 10, 2007
    Publication date: May 8, 2008
    Inventors: Kathleen A. Battista, Gilles C. Bignan, Peter J. Connolly, Stuart L. Emanuel, Stuart Hayden, Sigmond G. Johnson, Ronghui Lin, Steven A. Middleton, Niranjan B. Pandey, Mark T. Powell
  • Substituted triazole diamine derivatives as kinase inhibitors
    Patent number: 7317031
    Abstract: The present invention provides substituted triazole diamine derivatives as selective kinase or dual-kinase inhibitors and a method for treating or ameliorating a selective kinase or dual-kinase mediated disorder.
    Type: Grant
    Filed: February 1, 2005
    Date of Patent: January 8, 2008
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Ronghui Lin, Shenlin Huang, Steven K. Wetter, Peter J. Connolly, Stuart L. Emanuel, Robert H. Gruninger, Steven A. Middleton
  • Substituted triazine kinase inhibitors
    Patent number: 7205298
    Abstract: The present invention provides substituted 1,3,5-triazine compounds as kinase inhibitors and a method for treating or ameliorating a kinase mediated disorder.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: April 17, 2007
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Gee-Hong Kuo, Alan DeAngelis, Aihua Wang, Yan Zhang, Stuart L. Emanuel, Steve Middleton
  • Method to detect modulators of VEGF kinase domain
    Patent number: 7070938
    Abstract: The present invention relates to assays for the detection of compounds with pharmacological activity, particularly for the detection of modulators of rat vascular endothelial growth factor receptor (rat VEGF-R2) kinase domain.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: July 4, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Dana L. Johnson, Stuart L. Emanuel
  • Substituted triazole diamine derivatives as kinase inhibitors
    Patent number: 6924302
    Abstract: The present invention provides substituted triazole diamine derivatives as selective kinase or dual-kinase inhibitors and a method for treating or ameliorating a selective kinase or dual-kinase mediated disorder.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: August 2, 2005
    Assignee: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Ronghui Lin, Peter J. Connolly, Steven K. Wetter, Shenlin Huang, Stuart L. Emanuel, Robert H. Gruninger, Steven A. Middleton
  • Substituted triazine kinase inhibitors
    Publication number: 20040082581
    Abstract: The present invention provides substituted 1,3,5-triazine compounds as kinase inhibitors and a method for treating or ameliorating a kinase mediated disorder.
    Type: Application
    Filed: July 18, 2003
    Publication date: April 29, 2004
    Inventors: Gee-Hong Kuo, Alan DeAngelis, Aihua Wang, Yan Zhang, Stuart L. Emanuel, Steve Middleton
  • Substituted triazole diamine derivatives as kinase inhibitors
    Publication number: 20040077699
    Abstract: The present invention provides substituted triazole diamine derivatives as selective kinase or dual-kinase inhibitors and a method for treating or ameliorating a selective kinase or dual-kinase mediated disorder.
    Type: Application
    Filed: December 21, 2001
    Publication date: April 22, 2004
    Inventors: Ronghui Lin, Peter J. Connolly, Steven K. Wetter, Shenlin Huang, Stuart L. Emanuel, Robert H. Gruninger, Steve A. Middleton
  • Method to detect modulators of VEGF kinase domain
    Publication number: 20020037537
    Abstract: The present invention relates to assays for the detection of compounds with pharmacological activity, particularly for the detection of modulators of rat vascular endothelial growth factor receptor (rat VEGF-R2) kinase domain.
    Type: Application
    Filed: June 6, 2001
    Publication date: March 28, 2002
    Inventors: Dana L. Johnson, Stuart L. Emanuel